{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:23:44Z","timestamp":1789709024647,"version":"4.0.1"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2465,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1111\/j.1365-2133.2008.08851.x","type":"journal-article","created":{"date-parts":[[2008,9,25]],"date-time":"2008-09-25T08:28:35Z","timestamp":1222331315000},"page":"1217-1228","source":"Crossref","is-referenced-by-count":124,"title":["The impact of treatment with tumour necrosis factor-\u03b1 antagonists on the course of chronic viral infections: a review of the literature"],"prefix":"10.1093","volume":"159","author":[{"given":"S.","family":"Domm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cinatl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Mrowietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB2","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2005.06893.x","article-title":"British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005","volume":"153","author":"Smith","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB3","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","article-title":"Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection","volume":"62","author":"Peterson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB4","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.20702","article-title":"Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection","volume":"51","author":"Parke","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB5","first-page":"107","article-title":"Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C","volume":"31","author":"Oniankitan","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB6","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn\u2019s disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB8","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still\u2019s disease","volume":"30","author":"Michel","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB9","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/art.21216","article-title":"Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab","volume":"52","author":"Anelli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0168-8278(99)80060-9","article-title":"Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity","volume":"30","author":"Zylberberg","year":"1999","journal-title":"J Hepatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB12","first-page":"421","article-title":"Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis","volume":"35","author":"Cansu","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10067-006-0394-z","article-title":"Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases","volume":"26","author":"Aslanidis","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB14","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2005.11.1035","article-title":"Etanercept therapy in two patients with psoriasis and concomitant hepatitis C","volume":"54","author":"De Simone","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaad.2005.05.043","article-title":"Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection","volume":"54","author":"Rokhsar","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaad.2004.05.013","article-title":"Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases","volume":"51","author":"Magliocco","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/rheumatology\/kel191","article-title":"Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus","volume":"46","author":"Marotte","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D33627S2B6","article-title":"Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept)","volume":"12","author":"Cecchi","year":"2006","journal-title":"Dermatol Online J"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB19","first-page":"290","article-title":"Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities","volume":"17","author":"Vauloup","year":"2006","journal-title":"Eur Cytokine Netw"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1046\/j.1365-2249.1999.00812.x","article-title":"HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines","volume":"115","author":"Schlaak","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.19.1.65","article-title":"Noncytolytic control of viral infections by the innate and adaptive immune response","volume":"19","author":"Guidotti","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1525-1373.2000.22335.x","article-title":"Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis","volume":"223","author":"Herbein","year":"2000","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB23","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2007.10.011","article-title":"Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection","author":"Carroll","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB24","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection - natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB25","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3748\/wjg.v12.i6.974","article-title":"Subfulminant hepatitis B after infliximab in Crohn\u2019s disease: need for HBV-screening?","volume":"12","author":"Millonig","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1478-3231.2007.01665.x","article-title":"Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient","volume":"28","author":"Montiel","year":"2008","journal-title":"Liver Int"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB27","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1440-1746.2006.04559.x","article-title":"Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach","volume":"21","author":"Nathan","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2006.10.007","article-title":"Occult hepatitis B virus infection","volume":"46","author":"Raimondo","year":"2007","journal-title":"J Hepatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/104281903100006351","article-title":"Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy","volume":"44","author":"Rossi","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB30","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1053\/ajkd.2001.28607","article-title":"Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients","volume":"38","author":"Lee","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB31","first-page":"504","article-title":"Lamivudine in prevention and treatment of recurrent HBV after liver transplantation","volume":"3","author":"Lu","year":"2004","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB32","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1046\/j.1440-1746.2001.02532.x","article-title":"Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience","volume":"16","author":"Liu","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB34","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/kel123","article-title":"Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis","volume":"45","author":"Roux","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl.2","key":"10.1111\/j.1365-2133.2008.08851.x-BIB35","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.028209","article-title":"Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection","volume":"63","author":"Calabrese","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB36","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/rheumatology\/kem082","article-title":"Chronic viral hepatitis and TNF-alpha blockade","volume":"46","author":"Raftery","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tracli.2003.11.007","article-title":"Occult hepatitis B virus infection","volume":"11","author":"Allain","year":"2004","journal-title":"Transfus Clin Biol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJM199907013410104","article-title":"Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease","volume":"341","author":"Cacciola","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB39","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ard.2007.081513","article-title":"The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease","volume":"67","author":"Cepeda","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.rhu.0000260411.75599.39","article-title":"Successful etanercept use in an HIV-positive patient with rheumatoid arthritis","volume":"13","author":"Kaur","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jbspin.2006.05.012","article-title":"Use of infliximab to treat psoriatic arthritis in HIV-positive patients","volume":"74","author":"Sellam","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB42","first-page":"407","article-title":"Infliximab in the treatment of an HIV positive patient with Reiter\u2019s syndrome","volume":"30","author":"Gaylis","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB43","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.0007-0963.2004.05885.x","article-title":"Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab","volume":"150","author":"Bartke","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB44","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-4632.2005.02642.x","article-title":"Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients","volume":"45","author":"Ting","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB45","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/169.2.420","article-title":"Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic, and virologic parameters","volume":"169","author":"Aukrust","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-6405-3-8","article-title":"LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells","volume":"3","author":"Haraguchi","year":"2006","journal-title":"AIDS Res Ther"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00002030-200401230-00015","article-title":"A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis","volume":"18","author":"Wallis","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB48","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/BOR.0b013e3282f05b63","article-title":"Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections","volume":"19","author":"Vassilopoulos","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00054725-200403000-00004","article-title":"Epstein-Barr virus viral load in Crohn\u2019s disease: effect of immunosuppressive therapy","volume":"10","author":"Reijasse","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/s10165-008-0053-0","article-title":"Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis","volume":"315","author":"Komatsuda","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB51","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00296-007-0467-6","article-title":"Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment","volume":"28","author":"Park","year":"2008","journal-title":"Rheumatol Int"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB52","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ibd.20131","article-title":"Infliximab and the risk of latent viruses reactivation in active Crohn\u2019s disease","volume":"13","author":"Lavagna","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB53","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jbspin.2007.09.002","article-title":"EBV-specific T-cell response and immunosuppression by methotrexate and TNFalpha antagonists in patients with chronic inflammatory joint disease","volume":"74","author":"Miceli-Richard","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB54","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.22783","article-title":"Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase Epstein-Barr virus load in patients with rheumatoid arthritis","volume":"57","author":"Balandraud","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB55","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/rheumatology\/keh696","article-title":"Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis","volume":"44","author":"Torre-Cisneros","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB56","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/00042737-200212000-00018","article-title":"Disseminated cytomegalovirus infection in Crohn\u2019s disease following anti-tumour necrosis factor therapy","volume":"14","author":"Helbling","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB57","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1086\/425123","article-title":"Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis","volume":"39","author":"Haerter","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB58","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.3748\/wjg.14.2912","article-title":"Cytomegalovirus colitis in a patient with Beh\u00e7et\u2019s disease receiving tumor necrosis factor alpha inhibitory treatment","volume":"14","author":"Sari","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB59","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1086\/428672","article-title":"Cytomegalovirus hepatitis associated with use of anti-tumor necrosis factor-alpha antibody","volume":"40","author":"Mizuta","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB60","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1086\/500262","article-title":"Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody","volume":"42","author":"Kohara","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB61","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1128\/JVI.72.3.2316-2322.1998","article-title":"Distinct pathways for tumor necrosis factor alpha and ceramides in human cytomegalovirus infection","volume":"72","author":"Allan-Yorke","year":"1998","journal-title":"J Virol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB62","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/pmj.2003.014373","article-title":"Severe herpes zoster after infliximab infusion","volume":"80","author":"Kinder","year":"2004","journal-title":"Postgrad Med J"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB63","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/ard.61.7.661","article-title":"Shingles following infliximab infusion","volume":"61","author":"Baumgart","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB64","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0166-3542(91)90065-Y","article-title":"Effects of tumor necrosis factor alpha on replication of varicella-zoster virus","volume":"15","author":"Ito","year":"1991","journal-title":"Antiviral Res"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB65","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/j.1572-0241.2004.41389_7.x","article-title":"Disseminated primary varicella after initiation of infliximab for Crohn\u2019s disease","volume":"99","author":"Leung","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB66","doi-asserted-by":"crossref","first-page":"9814","DOI":"10.1073\/pnas.94.18.9814","article-title":"Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors","volume":"94","author":"Elkon","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB67","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1128\/JVI.73.6.5098-5109.1999","article-title":"Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung","volume":"73","author":"Peng","year":"1999","journal-title":"J Virol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB68","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/hep.510310317","article-title":"Fas- and tumor necrosis factor receptor 1-dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice","volume":"31","author":"Liu","year":"2000","journal-title":"Hepatology"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB69","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1189\/jlb.0103035","article-title":"The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection","volume":"74","author":"Kafrouni","year":"2003","journal-title":"J Leukoc Biol"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB70","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jinf.2006.03.025","article-title":"Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn\u2019s disease","volume":"54","author":"Ahmad","year":"2007","journal-title":"J Infect"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB71","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3904\/kjim.2007.22.1.63","article-title":"Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis","volume":"22","author":"Kang","year":"2007","journal-title":"Korean J Intern Med"},{"key":"10.1111\/j.1365-2133.2008.08851.x-BIB72","first-page":"513","article-title":"Increased tumor necrosis factor-alpha (TNF-alpha) gene expression in parainfluenza type 1 (Sendai) virus-induced bronchiolar fibrosis","volume":"152","author":"Uhl","year":"1998","journal-title":"Am J Pathol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2008.08851.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2008.08851.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T02:24:26Z","timestamp":1738376666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/159\/6\/1217\/6641533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08851.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}